



16.45 - 17.05:
Sleep and metabolism:
Potential for anti-obesity drug
developments

Integration of Multiple Systems in the Hypothalamus

- › Sleep
- › Circadian Rhythms
- › Feeding - Appetite
- › Metabolism
- › Sexual Behaviour - Puberty
- › Reproduction
- › Stress
- › Inflammation
- › Growth
- › Lactation



Integration of Multiple Systems in the Hypothalamus



Integration of Multiple Systems in the Hypothalamus

NEUROSEARCH

4

Pharmacological Treatments and the Hypothalamus: Target of Action outside.


NEUROSEARCH

5

Strategies for Finding new Treatments

NEUROSEARCH


6





NEUROSEARCH


Genotype	Glucosekonz. [mM]
C57BL/6J (n=4)	3.3 ± 1
C57BL/6J:Ob (n=4)	10 ± 1
C57BL/6J:Db (n=4)	22 ± 10

Expression analysis









Narcolepsy-cataplexy – An Autoimmune disease?

NEUROSEARCH

Excessive daytime sleepiness *EDS* and sleep attacks

Cataplexy

(muscle atonia triggered by positive/negative emotions, especially laughter, jokes and anger)

Sleep paralysis

(atonia at transition between sleep/awakening)

Hypnagogic hallucinations

(visual, auditive, tactile episodes at transition between sleep/awakening)

Stine Knudsen¹, Jens D. Mikkelsen², Poul Jennum¹

¹Danish Center for Sleep Medicine, Glostrup Hospital, and ²Neurosearch A/S, Denmark

13

Onset of Symptoms in Narcolepsy

NEUROSEARCH




Figure 3—Age at onset of sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis in 405, 405, 270 and 168 patients, respectively. Self-reported age of the various narcolepsy symptoms was ascertained from the Stanford Center for Narcolepsy Sleep Inventory. The number of subjects with onset at each age range is plotted. Note that sleepiness onset is generally earlier than the other symptoms.

Sleep. 2002 Feb 1;25(1):27-35.

14

Strong Genetic Factor in Narcolepsy

NEUROSEARCH

- 5-7% of patients have relatives with narcolepsy, (1. degree relatives: 20-40% increased risk of narcolepsy)
- 90% with cataplexy og 56% without cataplexy have at specific HLA-type (DQB1*0602), indicating a strong autoimmune component.


Sleep 1994;17(suppl 8):S4-S9 Lancet 1989;2:1376-79 Am J Hum Genet 2001;68:686-99

15

Specific Death(?) of Hypocretin neurons


NEUROSEARCH

- 85-100% reduction in hypocretin neurons in the hypothalamus
- Ca. 90% of narcolepsy-cataplexy have low levels of (<110 pg/ml) hypocretin-1 in the cerebrospinal fluid




The Hypothesis

NEUROSEARCH




Treatment Opportunities

NEUROSEARCH



The Danish Study – 9 patients for IgG tests																							
NEUROSEARCH																							
<p>HLA DQB1*0602-positive/negative and CSF-hypocretin</p> <p>4. Danish laboratory data</p> <table> <tr> <th>HLA-type</th><th>narcolepsy-cataplexy</th><th>narcolepsy without cataplexy</th></tr> <tr> <td>HLA-DQB1*0602-positive</td><td>100% (25/25)</td><td>35.71 % (5/14)</td></tr> <tr> <td>CSF-hypocretin</td><td></td><td></td></tr> <tr> <td>mean value (pg/ml)</td><td>40.34±98.67</td><td>379.47±155.61 ($p=0.0001$)</td></tr> <tr> <td><110 pg/ml</td><td>96.43% (27/28)</td><td>14.29% (2/14)</td></tr> <tr> <td>100-200 pg/ml</td><td>0% (0/28)</td><td>0% (0/14)</td></tr> <tr> <td>> 200 pg/ml</td><td>3.57% (1/28)</td><td>85.71 % (12/14)</td></tr> </table>			HLA-type	narcolepsy-cataplexy	narcolepsy without cataplexy	HLA-DQB1*0602-positive	100% (25/25)	35.71 % (5/14)	CSF-hypocretin			mean value (pg/ml)	40.34±98.67	379.47±155.61 ($p=0.0001$)	<110 pg/ml	96.43% (27/28)	14.29% (2/14)	100-200 pg/ml	0% (0/28)	0% (0/14)	> 200 pg/ml	3.57% (1/28)	85.71 % (12/14)
HLA-type	narcolepsy-cataplexy	narcolepsy without cataplexy																					
HLA-DQB1*0602-positive	100% (25/25)	35.71 % (5/14)																					
CSF-hypocretin																							
mean value (pg/ml)	40.34±98.67	379.47±155.61 ($p=0.0001$)																					
<110 pg/ml	96.43% (27/28)	14.29% (2/14)																					
100-200 pg/ml	0% (0/28)	0% (0/14)																					
> 200 pg/ml	3.57% (1/28)	85.71 % (12/14)																					
19																							

Narcolepsy: Autoantibodies against hypocretin neurons in serum/CSF?	
NEUROSEARCH	
<p>Methods:</p> <p>Serum (diluted 1:20 or 1:100) and CSF from 9 of our HLA-DQB1*0602-positive HCRT-deficient Narcolepsy-cataplexy patients and 9 age and gender matched controls.</p> <p>Patient data: age 14-63 years, disease duration 3-41 years, MSLT: sleep latency < 8 min and ≥2 SOREMPs CSF-hypocretin-1: <110 pg/ml</p> <p>Samples were each applied onto 6 coronal sections of paraformaldehyde-fixed adult male rat hypothalamus.</p> <p>Immunostaining was evaluated blind to the nature of the sample. Double-staining with anti-HCRT-IgG was done if positive immunostaining was found.</p>	
<p>NeuroReport. 18(1):77-79, (2007)</p> <p>20</p>	

Serum from a DQB1-0602-positive patient with narcolepsy-cataplexy binds to rat hypocretin neurons	
NEUROSEARCH	
	
<p>NeuroReport. 18(1):77-79, (2007)</p> <p>21</p>	

Results:

NEUROSEARCH

Immunostaining of HCRT-containing neurons was found in serum of one (of 9) narcolepsy patient. - Not in the CSF?!

Same result confirmed in an additional sample from the same patient taken 1 year and 3 months later.

Discussion and Perspectives

NEUROSEARCH

- > Not the right cellular target (neurons/axons outside hypothalamus)?
- > Antibody levels are too low for detection?
- > Antibodies are mainly present at disease onset?
- > It is not humoral (IgG) autoimmunity (but cellular)?
- > No Cross-reactivity between rat and human antigens
- > Fixation has destroyed the antigen

Thanks

NEUROSEARCH

Stine Knudsen and Poul Jennum
Danish Center for Sleep Medicine, Glostrup Hospital,

Rheoscience A/S
